 DBV Technologies SAs NASDAQ: DBVT pivotal Phase 3 EPITOPE trial of Viaskin Peanut 250 μg for peanut-allergic toddlers ages 1 to 3 years met its primary endpoint. Viaskin Peanut demonstrated a statistically significant treatment effect, with 67.0 of subjects in the. 